Year
- 2026
- 2025
In the News
June 2026 – OncLive
Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel Shows Encouraging Efficacy, Tolerability in First-Line Metastatic PDAC
June 2026 – BioWorld
Uprising in pancreatic space more than Revolution
June 2026 – Biotech TV
ASCO 2026: Immuneering presented an update of the P2 trial of its deep cyclic inhibitor of MEK in 1L pancreatic cancer at ASCO. CEO Ben Zeskind argues why competitor data should not overshadow this
June 2026 – BioSpace
ASCO: Biopharma has pancreatic cancer ‘surrounded’ as Immuneering’s drug adds 9 quality months
May 2026 – BioCentury
ASCO to spotlight pancreatic cancer innovation beyond KRAS
May 2026 – BioWorld
MEK inhibitor delivers 17.3-month OS for pancreatic cancer
May 2026 – BioSpace
Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes
March 2026 – Brew Markets
How Immuneering’s Journey Highlights the Biotech Markets Complexity, with CEO Ben Zeskind
March 2026 – The BioReport Podcast
Outsmarting resistance with rhythm
February 2026 – Healthcare Brew
Immuneering CEO shares his cancer drug development strategy
February 2026 – Pharmacy Times
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
February 2026 – CURE Today
New Combination Treatment Approach Studied in Pancreatic Cancer
February 2026 – Pharmacy Times
Improving Tolerability and Quality of Life in Pancreatic Cancer Treatment with Atebimetinib
February 2026 – Pharmaphorum
A cancer treatment modality that prioritises QoL, with Ben Zeskind
February 2026 – Pharmacy Times
Atebimetinib Signals a Potential Shift in First-Line Pancreatic Cancer Outcomes
January 2026 – Pharmacy Times
Immuneering Panel & CEO Insights: Atebimetinib Raises the Bar for Survival and Quality of Life in Pancreatic Cancer
January 2026 – Targeted Oncology
Atebimetinib Combo Shows Compelling 1-Year OS in First-Line Pancreatic Cancer
January 2026 – Rare Cancer
Atebimetinib nearly doubles 1-year survival in pancreatic cancer study
January 2026 – Fierce Biotech
Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution
January 2026 – FirstWord Pharma
Immuneering touts 'exceptional' 12-month OS for pancreatic cancer therapy
January 2026 – Endpoints News
Immuneering’s pancreatic cancer pill continues to beat standard care, updated first line data show
December 2025 – Clinical Trials Arena
Immuneering progresses MAPK inhibitor in lung and pancreatic cancer
December 2025 – Rare Cancer News
Pancreatic cancer treatment atebimetinib set for Phase 3 trial
October 2025 – BioTuesdays
Immuneering outpacing cancer with a novel approach to improving overall survival
October 2025 – BiotechTV
Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'
October 2025 – Let’s Win Pancreatic Cancer
Early nine-month data from a clinical trial suggests a new promising first-line treatment option for patients newly diagnosed with pancreatic cancer.
October 2025 – Targeted Oncology
Atebimetinib combined with modified gemcitabine/nab-paclitaxel shows remarkable survival rates in first-line pancreatic cancer, surpassing standard treatments.
October 2025 – OncLive
Atebimetinib Plus Chemo Makes Case As Potential Frontline Option in Pancreatic Cancer
September 2025 – OncLive
First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer
September 2025 – Endpoints News
Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this year
September 2025 – The Scientist
A Slow and Steady Approach to Pancreatic Cancer Therapy
July 2025 – Pharmaceutical Executive
Changing the Ways We Treat Cancer
July 2025 – Forbes
A Slow And Steady Approach To Cancer Fighting
July 2025 – PharmaVoice
The MEK effect on cancer — a slow and steady approach to drug resistance
June 2025 – Targeted Oncology
Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer
June 2025 – OncLive
Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer
June 2025 – Fierce Biotech
Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans
June 2025 – Cancer Network
Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC
June 2025 – FirstWord Pharma
Immuneering touts strong survival in pancreatic cancer trial
June 2025 – Endpoints News
Immuneering says MEK pill beats standard of care in first-line pancreatic cancer